Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 38.5(b) - Pfizer Inc.

4 Nov 2015 12:03

RNS Number : 5417E
J.P. Morgan Securities LLC
04 November 2015
Β 

Ap27

Β 

FORMΒ 38.5(b)

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 38.5(b)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DEALINGSΒ BYΒ CONNECTEDΒ EXEMPTΒ PRINCIPALΒ TRADERSΒ WITHOUTΒ RECOGNISEDΒ INTERMEDIARYΒ STATUS,Β ORΒ WITHΒ RECOGNISEDΒ INTERMEDIARYΒ STATUSΒ BUTΒ NOTΒ DEALINGΒ INΒ AΒ CLIENT-SERVINGΒ CAPACITY

Β 

Β 

1. KEYΒ INFORMATION

Β 

Name of exempt principal trader

J.P. Morgan Securities LLC.

Company dealt in

Pfizer Inc

Class of relevant security to which the dealings being disclosed relate (Note 1)

Common Stock

Date of dealing

03 November 2015

Β 

2. INTERESTSΒ ANDΒ SHORTΒ POSITIONS

Β 

(a) InterestsΒ andΒ shortΒ positionsΒ (followingΒ dealing)Β inΒ theΒ classΒ ofΒ relevantΒ securityΒ dealtΒ inΒ (NoteΒ 2)

Β 

Class of relevant security:

Long

Short

Common Stock

Number

(%)

Number

(%)

(1) Relevant securities

Β 5,251,185 0.09

3,898,952 0.06

(2) Derivatives (other than options)

1,099,067 0.02

Β 2,469,914 0.04

(3) Options and agreements to purchase/sell

Β 6,401,570 0.10

3,383,300 0.05

Total

12,751,822 0.21

9,752,166 0.15

Β 

Β 

Β 

(b) InterestsΒ andΒ shortΒ positionsΒ inΒ relevantΒ securitiesΒ ofΒ theΒ company,Β otherΒ thanΒ theΒ classΒ dealtΒ inΒ (NoteΒ 2)

Β 

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

Β 

Ap28

Β 

Β 

3. DEALINGSΒ (NoteΒ 3)

Β 

(a) PurchasesΒ andΒ sales

Β 

Purchases/ sales

Β 

Number of relevant securities

Price per unit (USD)

Purchases

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Sales

34.8016

34.8054

34.8200

34.8245

34.8281

34.8300

34.8312

34.8356

34.8638

34.9700

Β 

34.7850

34.7875

34.7900

34.7950

34.8000

34.8016

34.8050

34.8054

34.8075

34.8100

34.8150

34.8190

34.8197

34.8200

34.8207

34.8234

34.8243

34.8245

34.8250

34.8258

34.8265

34.8271

34.8281

34.8300

34.8305

34.8312

34.8324

34.8334

34.8338

34.8345

34.8346

34.8350

34.8356

34.8365

34.8390

34.8396

34.8399

34.8401

34.8419

34.8424

34.8430

34.8450

34.8485

34.8500

34.8549

34.8573

34.8582

34.8583

34.8592

34.8600

34.8617

34.8632

34.8650

34.8675

34.8700

34.8750

34.8754

34.8767

34.8800

34.8850

34.8900

34.8925

34.8950

34.9000

34.9005

34.9022

34.9040

34.9050

34.9100

34.9150

34.9200

34.9233

34.9250

34.9253

34.9300

34.9331

34.9333

34.9334

34.9350

34.9360

34.9396

34.9400

34.9450

34.9470

34.9473

34.9500

34.9550

34.9556

34.9577

34.9592

34.9600

34.9607

34.9608

34.9626

34.9640

34.9650

34.9663

34.9694

34.9700

34.9725

34.9750

34.9763

34.9800

34.9850

34.9852

34.9864

34.9880

34.9900

34.9933

34.9989

35.0000

35.0028

35.0050

35.0200

165,297

37,519

105

13,400

11,376

100

18,624

29,081

2,400

82,708

Β 

900

100

1,100

3,500

3,209

165,297

125,510

37,519

100

1,700

800

12,400

3,221

100

7,142

604

3,034

13,400

700

1,700

3,400

1,599

11,376

7,450

8,893

18,624

11,700

12,500

7,400

20,200

4,600

12,490

29,081

3,123

2,000

7,750

1,638

42,996

3,095

28,829

500

100,000

1,300

400

56,235

4,100

2,034

4,900

8,983

2,700

4,601

5,967

2,100

2,200

7,040

800

424

600

2,050

1,400

900

100

300

600

3,536

2,700

1,000

400

864

1,000

500

300

100

3,166

8,300

297

600

2,900

1,100

500

4,969

900

3,400

431

1,100

15,000

9,700

900

1,100

4,300

2,649

3,500

236

381

1,385

5,300

800

1,800

27,367

1,200

1,000

1,600

3,266

4,300

415

700

1,000

800

300

900

200

900

200

100

Β 

(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)

Β 

Product name,

e.g. CFD

Nature of transaction

(Note 5)

Number of relevant securities

(Note 6)

Price per unit (USD)

(Note 4)

Β 

(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities

Β 

Β 

(i) Writing,Β selling,Β purchasingΒ orΒ varying

Β 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 4)

Call Option

Put Option

Put Option

Purchasing

Purchasing

Selling

1,500,000

1,500,000

1,500,000

35.00

34.50

35.00

American

American

American

13/11/15

13/11/15

17/06/16

0.30

0.48

2.94

Β 

Β 

(ii) Exercising

Β 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 4)

+ bought by counterparty at exercise price

Β 

Β 

(d) OtherΒ dealingsΒ (includingΒ transactionsΒ inΒ respectΒ ofΒ newΒ securities)Β (NoteΒ 3)

Β 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

Β 

Ap29

Β 

4. OTHERΒ INFORMATION

Β 

Agreements,Β arrangementsΒ orΒ understandingsΒ relatingΒ toΒ optionsΒ orΒ derivatives

Β 

FullΒ detailsΒ ofΒ anyΒ agreement,Β arrangementΒ orΒ understandingΒ betweenΒ theΒ person disclosingΒ andΒ anyΒ otherΒ personΒ relatingΒ toΒ theΒ votingΒ rightsΒ ofΒ anyΒ relevantΒ securitiesΒ underΒ anyΒ optionΒ referredΒ toΒ onΒ thisΒ formΒ orΒ relatingΒ toΒ theΒ votingΒ rightsΒ orΒ futureΒ acquisitionΒ orΒ disposalΒ ofΒ anyΒ relevantΒ securitiesΒ toΒ whichΒ anyΒ derivative referredΒ toΒ onΒ thisΒ formΒ isΒ referenced.Β IfΒ none,Β thisΒ shouldΒ beΒ stated.

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

IsΒ aΒ SupplementalΒ FormΒ 38.5(b)Β attached?Β (NoteΒ 8) Β YES

Β 

Β 

Date of disclosure

04 November 2015

Contact name

Tung Le

Telephone number

020 7742 7272

Name of offeree/offeror with which connected

Allergan plc

Nature of connection (Note 9)

Adviser to Allergan plc

Β 

Β 

Β 

SUPPLEMENTALΒ FORMΒ 38.5(b)

Β 

Β 

Β 

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 38.5(b)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DETAILSΒ OFΒ OPENΒ POSITIONS

Β 

(ThisΒ formΒ shouldΒ beΒ attachedΒ toΒ FormΒ 38.5(b))Β OPENΒ POSITIONSΒ (NoteΒ 1)

Β 

Product name,

e.g. call option

Written or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)(USD)

Type, e.g. American, European etc.

Expiry date

Call option

Purchased

30,000

35.00

American

20/01/17

Call option

Purchased

70,000

37.00

American

20/01/17

Call option

Purchased

108,700

34.91

European

09/11/15

Call option

Purchased

113,900

35.00

American

15/01/16

Call option

Purchased

700

38.00

American

15/01/16

Call option

Purchased

200,000

34.00

American

20/11/15

Call option

Purchased

1,500,000

35.00

American

13/11/15

Call option

Written

Β 

2,500

28.00

American

15/01/16

Call option

Written

14,700

30.00

American

15/01/16

Call option

Written

200

37.00

American

15/01/16

Call option

Written

150,000

37.00

American

15/01/16

Call option

Written

50,000

33.00

American

18/12/15

Call option

Written

47,100

34.00

American

18/12/15

Call option

Written

7,600

32.00

American

15/01/16

Call option

Purchased

383,200

34.71

European

21/05/16

Call option

Purchased

383,200

34.71

European

21/05/16

Call option

Purchased

127,794

35.28

European

03/12/15

Call option

Purchased

120,533

35.66

European

12/01/16

Call option

Purchased

48,943

36.47

European

25/01/16

Call option

Purchased

295,700

36.49

European

05/11/15

Call option

Purchased

295,700

36.49

European

05/11/15

Call option

Purchased

192,000

37.12

European

10/11/15

Call option

Purchased

192,000

37.12

European

10/11/15

Call option

Purchased

200,000

33.00

European

16/12/15

Call option

Written

200,000

33.00

European

16/12/16

Call option

Written

383,200

34.71

European

21/12/15

Call option

Written

295,700

36.49

European

05/11/15

Call option

Written

192,000

37.12

European

10/11/15

Put option

Written

Β 

30,000

35.00

American

20/01/17

Put option

Written

Β 

20,000

35.00

American

20/01/17

Put option

Written

Β 

4,300

30.00

American

15/01/16

Put option

Written

Β 

2,800

28.00

American

15/01/16

Put option

Written

Β 

300

32.00

American

15/01/16

Put option

Written

Β 

150,000

30.00

American

16/09/16

Put option

Written

Β 

100,000

36.00

American

18/03/16

Put option

Written

Β 

32,900

32.00

American

15/01/16

Put Option

Written

1,500,000

35.00

American

17/06/16

Put option

Purchased

9,200

33.00

American

19/02/16

Put option

Purchased

19,100

31.00

American

19/02/16

Put option

Purchased

5,300

23.00

American

15/01/16

Put option

Purchased

100,000

30.00

American

15/01/16

Put option

Purchased

5,600

25.00

American

15/01/16

Put option

Purchased

250,000

28.00

American

15/01/16

Put option

Written

200,000

33.00

European

16/12/16

Put Option

Purchased

1,500,000

34.50

American

13/11/15

Put option

Purchased

450,000

35.00

American

15/01/16

Callable Barrier Reverse Convertible Note

Purchased

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Purchased

30,572

32.71

N/A

21/03/17

Auto-callable Barrier Reverse Convertible Note

Purchased

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Purchased

30,408

34.53

N/A

05/04/16

Equity Linked Note

Purchased

6,740

29.67

N/A

03/02/16

Leveraged Accumulator

Purchased

16,354+

29.12

N/A

12/09/16

Callable Barrier Reverse Convertible Note

Written

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Written

30,572

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Written

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Written

30,408

34.53

N/A

05/04/16

Equity Linked Note

Written

6,740

29.67

N/A

03/02/16

Leveraged Accumulator

Written

16,354+

29.12

N/A

12/09/16

Leveraged Accumulator

Written

10,200+

31.70

N/A

04/03/16

Auto-callable Optimization Securities

Written

7,851

27.60

N/A

25/06/20

Equity Linked Note

Written

6,740

29.67

N/A

03/02/16

Callable Barrier Reverse Convertible Note

Written

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Written

30,572

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Written

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Written

30,408

34.53

N/A

05/04/16

Leveraged Accumulator

Written

16,354+

29.12

N/A

12/09/16

Put Option

Purchased

457,000

27.50

N/A

11/01/16

Callable Barrier Reverse Convertible

Purchased

22,929

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Purchased

7,685

32.53

N/A

15/03/17

Auto-Callable Barrier Reverse Convertible Note

Purchased

11,189

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Purchased

178

2.44

N/A

05/04/2016

+ This instrument is physically settled, and the interest in shares has been calculated as the maximum number of Mylan shares that the counterparty could be obliged to buy at the exercise price

Β 

Notes

Β 

1. WhereΒ thereΒ areΒ openΒ optionΒ positionsΒ orΒ openΒ derivativeΒ positionΒ (exceptΒ forΒ CFDs),Β fullΒ detailsΒ shouldΒ beΒ given.Β FullΒ detailsΒ ofΒ any existingΒ agreementsΒ toΒ purchaseΒ orΒ toΒ sellΒ mustΒ alsoΒ beΒ givenΒ onΒ this form.

Β 

2. ForΒ allΒ pricesΒ andΒ otherΒ monetaryΒ amounts,Β theΒ currencyΒ mustΒ be stated.

Β 

ForΒ fullΒ detailsΒ ofΒ disclosureΒ requirements,Β seeΒ RulesΒ 8Β and

38.5Β ofΒ theΒ Rules.Β IfΒ inΒ doubt,Β consultΒ theΒ Panel.

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISEFSFFELFISESF
Date   Source Headline
4th Nov 20155:37 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20155:37 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20155:35 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20155:34 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20153:33 pmRNSForm 8.3 - Allergan plc
4th Nov 20153:30 pmRNSForm 8.3 - Pfizer Inc. - Amendment
4th Nov 20153:29 pmRNSForm 8.3 - Pfizer Inc.
4th Nov 20153:26 pmRNSForm 8.3 - Pfizer Inc.
4th Nov 20153:20 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20153:20 pmRNSForm 8.3 - PFIZER INC
4th Nov 20153:18 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20153:17 pmRNSForm 8.3 - ALLERGAN PLC
4th Nov 20153:07 pmBUSForm 8.3 - Pfizer Inc.
4th Nov 20153:06 pmRNSForm 8.3 - Pfizer Inc
4th Nov 20152:54 pmRNSForm 8.3 - Pfizer, Inc.
4th Nov 20152:27 pmRNSForm 8.3 - Pfizer Inc
4th Nov 20151:20 pmRNSForm 8.1 - [Pfizer Inc]
4th Nov 20151:16 pmRNSForm 38.5a
4th Nov 20151:13 pmRNSForm 38.5b
4th Nov 20151:12 pmRNSForm 38.5b
4th Nov 201512:03 pmRNSForm 38.5(b) - Pfizer Inc.
4th Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
4th Nov 201511:42 amRNSForm 38.5(a) - Pfizer Inc.
4th Nov 201511:33 amRNSRule 8.1 - Pfizer INC
4th Nov 201511:32 amRNSRule 38.5 - Pfizer INC
4th Nov 201511:32 amRNSRule 38.5 - Pfizer INC
4th Nov 201511:31 amRNSRule 38.5 - Pfizer INC
3rd Nov 20156:04 pmRNSForm 38.5a
3rd Nov 20156:02 pmRNSForm 38.5b
3rd Nov 20156:01 pmRNSForm 8.1 - [Pfizer]
3rd Nov 20155:57 pmRNSForm 8.1 - [Pfizer]
3rd Nov 20155:55 pmRNSForm 38.5b
3rd Nov 20153:49 pmRNSForm 8.3 - Allergan plc
3rd Nov 20153:31 pmRNSForm 8.3 - Pfizer Inc
3rd Nov 20153:20 pmRNSForm 8.3 - [PFIZER INC]
3rd Nov 20153:15 pmRNSForm 8.3 - Pfizer, Inc.
3rd Nov 20153:00 pmRNSForm 8.3 - PFIZER INC
3rd Nov 20152:59 pmRNSForm 8.3 - ALLERGAN PLC
3rd Nov 20152:57 pmRNSForm 8.3 - Pfizer Inc. - Amendment
3rd Nov 20152:55 pmRNSForm 8.3 - Pfizer Inc.
3rd Nov 20152:35 pmRNSForm 8.3 - Pfizer Inc
3rd Nov 20152:32 pmBUSForm 8.3 - Pfizer Inc.
3rd Nov 20152:15 pmRNSForm 8.3 - Allergan Plc
3rd Nov 201512:01 pmRNSForm 38.5(b) - Pfizer Inc.
3rd Nov 201511:56 amRNSRule 38.5 - Pfizer INC
3rd Nov 201511:54 amRNSRule 38.5 - Pfizer INC
3rd Nov 201511:54 amRNSRule 38.5 - Pfizer INC
3rd Nov 201511:09 amRNSForm 38.5(b) - Pfizer Inc.
3rd Nov 201511:08 amRNSForm 38.5(b) - Pfizer Inc.- Amendment
3rd Nov 20157:00 amRNSForm 8.3 - Pfizer, Inc.

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.